Michael I Polkey1, Zhi-Hui Qiu2, Lian Zhou2, Meng-Duo Zhu2, Ying-Xin Wu2, Yong-Yi Chen2, Sheng-Peng Ye3, Yu-Shan He3, Mei Jiang2, Bai-Ting He2, Bhavin Mehta1, Nan-Shan Zhong2, Yuan-Ming Luo4. 1. NIHR Respiratory Biomedical Research Unit at the Royal Brompton & Harefield NHS Foundation Trust and Imperial College, London, UK. 2. State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China. 3. Xing-Ning People's Hospital, Meizhou, Guangdong, China. 4. State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China. Electronic address: y.m.luo@vip.163.com.
Abstract
BACKGROUND: In COPD, functional status is improved by pulmonary rehabilitation (PR) but requires specific facilities. Tai Chi, which combines psychological treatment and physical exercise and requires no special equipment, is widely practiced in China and is becoming increasingly popular in the rest of the world. We hypothesized that Tai Chi is equivalent (ie, difference less than ±4 St. George's Respiratory Questionnaire [SGRQ] points) to PR. METHODS: A total of 120 patients (mean FEV1, 1.11 ± 0.42 L; 43.6% predicted) bronchodilator-naive patients were studied. Two weeks after starting indacaterol 150 μg once daily, they randomly received either standard PR thrice weekly or group Tai Chi five times weekly, for 12 weeks. The primary end point was change in SGRQ prior to and following the exercise intervention; measurements were also made 12 weeks after the end of the intervention. RESULTS: The between-group difference for SGRQ at the end of the exercise interventions was -0.48 (95% CI PR vs Tai Chi, -3.6 to 2.6; P = .76), excluding a difference exceeding the minimal clinically important difference. Twelve weeks later, the between-group difference for SGRQ was 4.5 (95% CI, 1.9 to 7.0; P < .001), favoring Tai Chi. Similar trends were observed for 6-min walk distance; no change in FEV1 was observed. CONCLUSIONS: Tai Chi is equivalent to PR for improving SGRQ in COPD. Twelve weeks after exercise cessation, a clinically significant difference in SGRQ emerged favoring Tai Chi. Tai Chi is an appropriate substitute for PR. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02665130; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND: In COPD, functional status is improved by pulmonary rehabilitation (PR) but requires specific facilities. Tai Chi, which combines psychological treatment and physical exercise and requires no special equipment, is widely practiced in China and is becoming increasingly popular in the rest of the world. We hypothesized that Tai Chi is equivalent (ie, difference less than ±4 St. George's Respiratory Questionnaire [SGRQ] points) to PR. METHODS: A total of 120 patients (mean FEV1, 1.11 ± 0.42 L; 43.6% predicted) bronchodilator-naive patients were studied. Two weeks after starting indacaterol 150 μg once daily, they randomly received either standard PR thrice weekly or group Tai Chi five times weekly, for 12 weeks. The primary end point was change in SGRQ prior to and following the exercise intervention; measurements were also made 12 weeks after the end of the intervention. RESULTS: The between-group difference for SGRQ at the end of the exercise interventions was -0.48 (95% CI PR vs Tai Chi, -3.6 to 2.6; P = .76), excluding a difference exceeding the minimal clinically important difference. Twelve weeks later, the between-group difference for SGRQ was 4.5 (95% CI, 1.9 to 7.0; P < .001), favoring Tai Chi. Similar trends were observed for 6-min walk distance; no change in FEV1 was observed. CONCLUSIONS: Tai Chi is equivalent to PR for improving SGRQ in COPD. Twelve weeks after exercise cessation, a clinically significant difference in SGRQ emerged favoring Tai Chi. Tai Chi is an appropriate substitute for PR. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02665130; URL: www.clinicaltrials.gov.
Authors: Zejun Liang; Qian Wang; Chenying Fu; Rui Liu; Lu Wang; Gaiqin Pei; Lin Xu; Chengqi He; Quan Wei Journal: Qual Life Res Date: 2021-08-12 Impact factor: 4.147
Authors: Elizabeth A Gilliam; Karen L Kilgore; Yuchen Liu; Lauren Bernier; Shana Criscitiello; Daniel Litrownik; Peter M Wayne; Marilyn L Moy; Gloria Y Yeh Journal: Respir Med Date: 2021-05-15 Impact factor: 4.582
Authors: Lowie E G W Vanfleteren; Iñigo Ojanguren; Claire M Nolan; Frits M E Franssen; Vasileios Andrianopoulos; Aleksandar Grgic; Marlies van Dijk; Dirk Jan Slebos; Luke Daines; Janwillem W H Kocks; Nicolas Kahn Journal: ERJ Open Res Date: 2019-02-11
Authors: Kristen M Kraemer; Daniel Litrownik; Marilyn L Moy; Peter M Wayne; Douglas Beach; Elizabeth S Klings; Harry Reyes Nieva; Adlin Pinheiro; Roger B Davis; Gloria Y Yeh Journal: COPD Date: 2021-06-09 Impact factor: 2.069